HP
AKRO

HealthInvest Partners’s Akero Therapeutics AKRO Stock Holding History

HealthInvest Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,432
Closed -$617K – 39
2024
Q1 		$617K Buy
24,432
+9,000
+58% +$216K 0.38% 40
2023
Q4 		$360K Buy
+15,432
New +$304K 0.28% 44
2022
Q4 		$9.1K Buy
+166
New +$7.11K 0.02% 39

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HealthInvest Partners's AKRO Position: Q2 2024 in Review

HealthInvest Partners sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 24,432 shares — an estimated $617K sold.

HealthInvest Partners first reported a position in AKRO in Q4 2022 and held it in 3 quarters. The position peaked at $617K in Q1 2024. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

  • HealthInvest Partners reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HealthInvest Partners sold 24,432 Akero Therapeutics shares in Q2 2024, an estimated $617K.
  • HealthInvest Partners first reported a position in Akero Therapeutics in Q4 2022 and held it in 3 quarters.
  • HealthInvest Partners's Akero Therapeutics position peaked at $617K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on HealthInvest Partners's 13F filing for Q2 2024, filed 14 Aug 2024.